In one of the largest rounds of financing announced for a North Carolina company this year, BioStratum said Monday it had closed on $20 million in financing.

Investors include HealthCap of Sweden, MP Bio hf of Iceland, Equity Resources Group of Cambridge, MA and BankInvest of Denmark.

At the same time, BioStratum announced in had acquired BioCrine AB, a startup focused on the treatment of diabetes. Terms were not disclosed.

BioStratum is focused on treatments on diabetes and cancer.

The top North Carolina deal before Monday’s announcement was $13 million for Norak Biosciences.